Sigma bioblogs (3 Jun 2011)
Sherman Ku PhD interview
The Scripps Research Institute, Member of the Gottesfeld Lab
What is the focus of your research?
My research has focused on developing an induced pluripotent stem cell (iPSC) model of Friedreich’s ataxia (FRDA), which is ..... read more....
Saturday, June 11, 2011
Edison Pharmaceuticals Announces Results of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial in the Mitochondrial Disease- Friedreich's Ataxia
10th of June 2011
MOUNTAIN VIEW, Calif., June 10, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia.
EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS).
Read more
MOUNTAIN VIEW, Calif., June 10, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia.
EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS).
Read more
Subscribe to:
Posts (Atom)
